Skip to main content

Industry News

Join WhatsApp Channel 

Regulatory Affairs Courses
  • SkylineDx, a Dutch-based innovative biotechnology company specialising in the development and commercialization of genetic tests, has launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods.

    [adsense:336x280:8701650588]

  • Lupin, India's fifth largest drug maker, announced the acquisition of Russia's Biocom, a fast-growing generic pharmaceuticals firm, for an undisclosed amount.
    Lupin Chief Executive Officer, Vinita Gupta, said: "We are excited about our entry into the Russian market through Biocom. Russia is an attractive market and this acquisition will also enable our expansion into neighbouring markets as well as other Eastern European markets in the future."

  • Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, launch generic Aggrenox (aspirin/extended-release dipyridamole) capsules in the United States which are used to lower the risk of stroke in people who have had a mini-stroke (transient ischemic attack or TIA) or stroke due to a blood clot.

  • US Food and Drug Administration (FDA) has granted marketing authorisation for morphine sulfate ER tablets. A subsidiary of Zydus Pharmaceuticals (USA) Inc., Nesher has considerable expertise in niche therapies with development or products barriers, such as controlled release medications and DEA-controlled substances. Morphine sulfate ER tablets used in the treatment of chronic pain or cancer related pain. The product will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St. Louis, USA.

  • 'Mulmin vitamin drops' is a combination of synthetic vitamins and minerals meant for children of one year age. However, the Food Safety and Standards Authority of India (FSSAI) issued a notice to the company to stop manufacture, sale, distribution and import of Mulmin drops and recall the existing products from the market with immediate effect.

  • Hilleman Laboratories is a first-of-its-kind joint-venture partnership formed between Merck & Co., a global research-driven pharmaceutical organization and Wellcome Trust, a global charitable foundation dedicated to human and animal health by supporting the brightest minds. Hilleman Laboratories (HL)  claimed to have made a break-through research  on the success of a preclinical trial conducted for Haemophilus influenza type b (Hib) vaccine offering hope to millions of children and needy people. Hilleman Laboratories announced the publication of an original scientific report in the journal 'Vaccine' based on the success of a pre-clinical trial conducted for the vaccine.

  • (NewsVoir); UCB, a multinational biopharmaceutical company, and Genpact (NYSE: G), a global leader in designing, transforming, and running intelligent business operations, have received the Aecus Innovation Award in recognition of their close collaboration in driving transformation that achieved far-reaching operational efficiencies in UCB’s global business services (GBS) finance organization.

  • A new study conducted at Saint Louis University has found a way to stop cancer cell growth. The study appeared in Cancer Cell.

    "Cancer cells look for metabolic pathways to find the parts to grow and divide. If they don't have the parts, they just die," said Thomas Burris, chair of pharmacology and physiology at Saint Louis University, US.

Subscribe to Industry News